Detail akcie Nanobiotix online

Business Summary: Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Nanobiotix SA revenues was not reported. Net loss applicable to common stockholders increased 7% to EUR28.1M. Higher net loss reflects Foreign Exchange Gain/Loss – Non-Busines decrease of 85% to EUR370K (income), Other Research and Development Expense increase of 14% to EUR12M (expense), Other SGA increase of 27% to EUR5.4M (expense).